Clinical pharmacokinetics of prazosin--1985.
Prazosin is a selective alpha 1-adrenoceptor antagonist which is useful alone or in combination for the treatment of hypertension and heart failure. Unlike many other antihypertensive drugs, the action of prazosin appears to be closely related to its concentration in plasma or whole blood. Prazosin is variably absorbed, is subject to first-pass metabolism, and is eliminated almost entirely as metabolites of much lower hypotensive activity than the parent drug. Prazosin is highly bound to plasma and tissue proteins. The influences of renal, hepatic and cardiac disease on the disposition of prazosin are reviewed, as are the effects of pregnancy and ageing. The optimum use of prazosin in clinical practice depends on an understanding of the pharmacokinetic properties of the drug.
D000375:Aging; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D005767:Gastrointestinal Diseases / Q000378:metabolism; D006333:Heart Failure / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000378:metabolism; D007408:Intestinal Absorption; D007674:Kidney Diseases / Q000378:metabolism; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism; D011224:Prazosin / Q000378:metabolism*; D011247:Pregnancy; D011485:Protein Binding; D011799:Quinazolines / Q000378:metabolism*; D014018:Tissue Distribution
D011799:Quinazolines; D011224:Prazosin